Sovaldi

June 6, 2017June 6, 2017

Sofosbuvir Reduces Transplant Need and Mortality Rates in Hepatitis C Patients, Study Finds

Hepatitis C, News

Sofosbuvir (sold under the brand name Sovaldi from Gilead Sciences, among others) significantly reduces the risk of death and the need for liver transplant in patients with hepatitis C who suffer from advanced stages ... Read more

April 10, 2017April 10, 2017

FDA Approves Sovaldi and Harvoni for Pediatric Hepatitis C Patients

Hepatitis C, News

Sovaldi (sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) were recently added to the list of approved medications for the treatment of hepatitis C virus (HCV) in pediatric patients ages 12 to 17 by the ... Read more

December 20, 2016December 20, 2016

Hepatitis C Therapy Sovaldi Can Adversely Interact with HIV Therapy Viread, Study Says

Hepatitis C, News

The hepatitis C drug Sovaldi (sofosbuvir) can adversely interact with the human immunodeficiency virus (HIV) drug Viread (tenofovir disoproxil), according to recent findings. Both drugs are manufactured and commercialized by Gilead ... Read more

July 5, 2016July 5, 2016

MassHealth Expands Access to Hepatitis C Therapies Like Harvoni

Hepatitis C, News

Leaders in Massachusetts recently took steps to ensure that all members of MassHealth, the state’s health insurance program for low- and moderate-income residents, have access to medications to treat hepatitis C. Following months of negotiations, MassHealth ... Read more

June 22, 2015July 2, 2015

China Rejects Gilead Patent Bid On $1,000-A-Day Hepatitis C Drug Sovaldi (Sofobuvir)

News

In response to news that the Chinese government patent office has denied a request by Gilead Sciences for a key patent on the hepatitis C drug sofosbuvir (trade name Sovaldi) ... Read more

April 28, 2015April 28, 2015

Gilead’s Drugs Harvoni and Sovaldi Prove to Be Safe and Effective in Patients with Advanced Liver Disease Associated with HCV

Hepatitis C, News

Gilead Sciences, Inc. recently announced in a press release the promising results from several Phase 2 clinical trials assessing the use of Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg) and Sovaldi® (sofosbuvir ... Read more

April 7, 2015April 7, 2015

British Columbia Provides Public Coverage For New Hepatitis C Drugs

Hepatitis C, News

Two new hepatitis C drugs that have proved remarkably effective against the disease are now covered under British Columbia’s public drug plan. The provincial government recently announced that both Harvoni and Sovaldi are now covered, ... Read more

March 26, 2015March 26, 2015

FDA Warns about Cardiac Risks Associated With HCV Drug Combination Amiodarone and Sofosbuvir

Hepatitis C, News

The U.S. Food and Drug Administration (FDA) recently announced a drug safety modification regarding the Warnings and Precautions, Adverse Reactions and Drug Interactions sections for Sovaldi and Harvoni medications. Sovaldi ... Read more

March 5, 2015March 6, 2015

Gilead Hands Over Sofosbuvir Distribution in India to Mylan

Hepatitis C, News

The Indian subsidiary of Mylan Inc. has signed an agreement with biopharmaceutical company Gilead Sciences to receive the rights as exclusive distributor in India of both Sovaldi and Harvoni — therapies designed to treat ... Read more

January 26, 2015January 26, 2015

Gilead’s Hepatitis C Treatment Sofosbuvir Rejected in India

News

Gilead Sciences, Inc.‘s application to commercialize novel hepatitis C treatment sofosbuvir in India has been rejected by the country’s patent office, as reported by Reuters. The refusal may open a new ... Read more